Is Cynapsus Therapeutics Inc a Buy? The Stock Rises Again


The stock of Cynapsus Therapeutics Inc (TSE:CTH) is a huge mover today! About 22,328 shares traded hands or 48.12% up from the average. Cynapsus Therapeutics Inc (TSE:CTH) has risen 190.06% since February 10, 2016 and is uptrending. It has outperformed by 173.57% the S&P500.
The move comes after 5 months positive chart setup for the $650.69 million company. It was reported on Sep, 13 by We have $73.25 PT which if reached, will make TSE:CTH worth $253.77M more.

Cynapsus Therapeutics Inc is a Canada specialty central nervous system pharmaceutical company. The company has a market cap of $650.69 million. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). It currently has negative earnings. The Firm completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply